Neurol. praxi. 2014;15(1):52

Diflunisal - nová možnosť účinnej farmakologickej liečby familiárnej amyloidnej polyneuropatie?

doc. MUDr. Peter Špalek, PhD.
Centrum pre neuromuskulárne ochorenia, Neurologická klinika SZU, Univerzitná nemocnica Bratislava – Ružinov

Komentář k článku „Familiárna amyloidná polyneuropatia“ Neurol. prax 2013, 14(6): 296–300.

Keywords:  

Published: March 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Špalek P. Diflunisal - nová možnosť účinnej farmakologickej liečby familiárnej amyloidnej polyneuropatie? Neurol. praxi. 2014;15(1):52.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Špalek P. Familiárna amyloidná polyneuropatia. Neurol prax 2013; 14: 296-300.
    2. Coelho T, Maia LF, da Silva AM, Cruz MW, Planté-Bordeneuve V, Lozeron P, Suhr OB, Campistol JM, Conceicao IM, Schmidt HHJ, Trigo P, Kelly JW, Chan J, Pack, am J, Wilson A, Grogan Dr. Tafamidis for transthyretin familial amyloid-polyneuropathy - a randomized, controlled trial. Neurology 2012; 79: 785-792. Go to original source... Go to PubMed...
    3. Berk JL, Suhr OB, Obici L, Sekima Y, Zeldenrust SR, Yamashita T, Heneghan MA, Gorevic PD,, ,itchy WJ, Wiesman JF, Nordh E, Corato M, Lozza A, Cortese A, Robinson-Papp J, Colton T, Rybin DV, Bisbee AB, Ando Y, Ikeda SI, Seldin DC, Merlini G, Skinner M, Kelly JW, Dyck JP. for the Diflunisal Trial Consortuim. Repurposing Diflunisal for Familial Amyloid Polyneuropathy A Randomized Clinical Trial. JAMA; 310(24): 3658-2667. Go to original source... Go to PubMed...

    Return to the content


    Neurology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.